AMERICAN CYTOGENETICS INC
NT 10-Q, 1996-12-16
MEDICAL LABORATORIES
Previous: BESTWAY INC, 10-Q, 1996-12-16
Next: AMERICAN NATIONAL INCOME FUND INC, 497, 1996-12-16



<PAGE>   1
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                  FORM 12b-25

                              Commission File Number 0-6375

                          NOTIFICATION OF LATE FILING

(Check One): [ ]  Form 10-K   [ ] Form 11-K   [ ]  Form 20-F   [X] Form 10-Q
[ ]  Form N-SAR

For Period Ended: October 31, 1996
- -----------------------------------------------------------

[ ]  Transition Report on Form 10-K      [ ]  Transition Report on Form 10-Q
[ ]  Transition Report on Form 20-F      [ ]  Transition Report on Form 11-K
[ ]  Transition Report on Form N-SAR
For the Transition Period Ended:

Nothing in this form shall be construed to imply that the Commission 
has verified any information contained herein.

If the notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification relates: N/A
                                                        --------------------

                         PART I. REGISTRANT INFORMATION

Full Name of registrant  American Cytogenetics, Inc..
                         --------------------------------------------------

Former name if applicable
                              N/A
- ---------------------------------------------------------------------------

Address of principal executive office (Street and number)

6440 Coldwater Canyon Avenue
- - ---------------------------------------------------------------------------

City, State and Zip Code  North Hollywood, CA 91606
                        ---------------------------------------------------

                        PART II. RULE 12b-25 (b) and (c)

If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed.  (Check box if appropriate)

[X]  (a) The reasons described in reasonable detail in Part III of this form
     could not be eliminated without unreasonable effort or expense;

[X]  (b) The subject annual report, semi-annual report, transition report on
     Form 10-K, 20-F, 11-K or Form N-SAR, or portion thereof will be filed on
     or before the 15th calendar day following the prescribed due date; or the
     subject quarterly report or transition report on Form 10-Q, or portion
     thereof will be filed on or before the fifth calendar day following the
     prescribed due date; and

[  ]     (c)  The accountant's statement or other exhibit required by Rule
        12b-25(c) has been attached if applicable.


                              PART III.  NARRATIVE

State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F,
10-Q, N-SAR or the transition report portion thereof could not be filed within
the prescribed time period.

        The registrant, whose fiscal quarter ended October 31, 1996, is not able
to file its quarterly report on Form 10-Q within the prescribed time period
because the registrant has been unable to timely finalize financial statements
relating to such period.

<PAGE> 2
                          PART IV.  OTHER INFORMATION

        (1)     Name and telephone number of person to contact in regard to
this notification

     Eric W. Hoffman              (818)               766-1286
- -------------------------------------------------------------------------------
          (Name)                 (Area Code)       (Telephone Number)

        (2)     Have all other periodic reports required under Section 13 or
15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter period
that the registrant was required to file such report(s) been filed?  If the
answer is no, identify report(s).
                                                              [X] Yes   [  ] No

        (3)     Is it anticipated that any significant change in results of
operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or
portion thereof?

               See Exhibit A, attached hereto.                [  ] Yes   [X] No

        If so, attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the reasons why a
reasonable estimate of the results cannot be made.

                      American Cytogenetics, Inc.
- ------------------------------------------------------------------------------
                  (Name of registrant as specified in charter)

has caused this notification to be signed on its behalf by the undersigned
thereunder duly authorized.

Date:  December , 1996                 By: /s/ Eric W. Hoffman
     -------------------                   ----------------------------
                                                Eric W. Hoffman
                                                Chief Financial Officer




© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission